← Back to Treatments
🏅 FDA Orphan Designation

WAINUA

EPLONTERSEN

Manufacturer: AstraZeneca Pharmaceuticals LP

Indicated for:
Hereditary ATTR amyloidosisOrphanHereditary transthyretin-mediated amyloidosisOrphan

FDA-Approved Indications (2)

Hereditary ATTR amyloidosisOrphan Designation

1 INDICATIONS AND USAGE WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleo…

Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Indications & Usage

1 INDICATIONS AND USAGE WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ( 1 )

💙 Support Programs

View all →
WAINUA
AstraZeneca Pharmaceuticals LP
Apply ↗
WAINUA
AstraZeneca
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.